Though the phenomenon of siRNA is now a key tool in drug development, it does have a fundamental disadvantage. Since siRNAs silence expression at the mRNA stage, it is presumed that siRNA drugs would need to be administered indefinitely. In a recent review article by N. Kolevzon and E. Yavin, the concept of a photoactivated TFO is proposed as a viable therapeutic option… Read More.

Have a question about therapeutic oligonucleotides? Post a comment below.